Physician profile
Brian H Kahn
NPI 1609879907
$500.73
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $152.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.64 | 2019 | |
| Amgen INC. | $54.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.72 | 2019 | |
| Amarin Pharma, INC. | $44.27 | 2019 | |
| Genentech USA, INC. | $24.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.97 | 2019 | |
| Pfizer INC. | $11.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.